Trial Profile

Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Envafolimab (Primary) ; Tucidinostat (Primary)
Indications HIV infections
Focus Therapeutic Use

Most Recent Events

25 Jul 2023 According to an Ascletis media release, results from this trial were presented at the 12th International AIDS Society (IAS) Conference on HIV Science.
25 Jul 2023 Results presented in an Ascletis Media Release.
15 Sep 2022 Planned End Date changed from 31 May 2023 to 31 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com